Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Oncology Regulatory Science

Richard Pazdur

理查德·帕兹杜尔

MD

🏢FDA Oncology Center of Excellence(美国食品药品监督管理局肿瘤卓越中心)🌐USA

Director, Oncology Center of Excellence肿瘤卓越中心主任

62
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Richard Pazdur has led FDA oncology drug review for over two decades, pioneering accelerated approval and breakthrough therapy designation pathways that transformed access to novel cancer therapies. He oversaw approval of hundreds of oncology drugs, reshaping the global regulatory landscape.

Share:

🧪Research Fields 研究领域

Drug Regulation药物监管
Accelerated Approval加速审批
Breakthrough Therapy Designation突破性疗法认定
Oncology Drug Approval肿瘤药物审批

🎓Key Contributions 主要贡献

Accelerated Approval Pathway

Championed and operationalized FDA's accelerated approval program for oncology, enabling faster patient access to promising therapies based on surrogate endpoints while confirmatory trials continue.

Breakthrough Therapy Designation

Instrumental in implementing breakthrough therapy designation for oncology drugs, streamlining development and review of transformative treatments for serious cancers.

Oncology Drug Review Leadership

Oversaw FDA approval of more than 300 oncology drugs and indications, fundamentally advancing the regulatory science of cancer therapeutics.

Representative Works 代表性著作

[1]

Accelerated Approval of Cancer Drugs — Missing Pieces of the Puzzle

New England Journal of Medicine (2019)

Outlined the rationale, successes, and ongoing challenges of the accelerated approval pathway for oncology drugs.

[2]

The FDA and the Accelerated Approval of Cancer Therapies

Nature Reviews Clinical Oncology (2021)

Comprehensive review of FDA regulatory innovation in oncology including real-world evidence integration.

[3]

Progression-Free Survival: An Important End Point in Evaluating Therapy in Advanced Colorectal Carcinoma

Journal of Clinical Oncology (1992)

Early landmark paper influencing use of surrogate endpoints in oncology regulatory submissions.

🏆Awards & Recognition 奖项与荣誉

🏆American Society of Clinical Oncology (ASCO) Statesman Award
🏆FDA Commissioner's Special Citation
🏆Public Service Award, National Academy of Medicine

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 理查德·帕兹杜尔 的研究动态

Follow Richard Pazdur's research updates

留下邮箱,当我们发布与 Richard Pazdur(FDA Oncology Center of Excellence)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment